Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To evaluate the activity of SU011248 in cytokine-refractory metastatic RCC when administered in a continuous treatment regimen - To evaluate the safety and tolerability of SU011248 administered in a continuous treatment regimen - To evaluate the tolerability of SU011248 administered in the morning versus in the evening prior to sleep - To assess patient reported outcomes (PRO) - To determine SU011248 and SU012662 trough concentrations (Ctrough) for evaluation of steady-state pharmacokinetics -To explore the correlations of potential biomarkers with clinical outcomes
Critère d'inclusion
- Histologically confirmed renal cell carcinoma with metastases with a component of clear (conventional) cell histology